Brooklyn Investment Group Takes $80,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Brooklyn Investment Group bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, HoldingsChannel reports. The firm bought 986 shares of the medical equipment provider’s stock, valued at approximately $80,000.

Other institutional investors have also added to or reduced their stakes in the company. Cetera Investment Advisers increased its position in shares of Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after acquiring an additional 13,380 shares during the period. Andra AP fonden raised its position in shares of Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after buying an additional 66,000 shares during the last quarter. Swedbank AB raised its holdings in shares of Hologic by 5.2% during the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after acquiring an additional 80,575 shares during the period. GAMMA Investing LLC raised its position in shares of Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares during the period. Finally, Comerica Bank lifted its holdings in shares of Hologic by 40.9% in the 1st quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock worth $8,580,000 after acquiring an additional 31,967 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.6 %

Shares of NASDAQ:HOLX opened at $79.44 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The firm has a fifty day moving average of $80.28 and a two-hundred day moving average of $78.42. The firm has a market capitalization of $18.45 billion, a P/E ratio of 23.86, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.89 EPS. On average, equities analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HOLX shares. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Raymond James raised their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.